In addition to paving the way for regulatory filings, Merck & Co. Inc.’s pivotal data for bezlotoxumab sheds light on the nature of the gastrointestinal infection Clostridium difficile and for the potential role of monoclonal antibodies in preventing recurrence of the condition, as well as in infectious disease more broadly.
Currently, no drug is approved for preventing recurrence of C. difficile and the disease burden is large. Merck notes that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?